Literature DB >> 31309922

Severe Yellow Fever and Extreme Hyperferritinemia Managed with Therapeutic Plasma Exchange.

Jaques Sztajnbok1, Ceila Maria Sant'Ana Malaque1, Camila Hitomi Nihei1, Irene Faria Duayer1, Zita Maria Leme Britto1, Eduarda Gambini Beraldo1, Ralcyon Francis AzevedoTeixeira1.   

Abstract

A 43-year-old man was admitted to the intensive care unit and diagnosed with yellow fever. He presented with refractory bleeding, extreme hyperferritinemia, and multiple organ dysfunction syndrome, requiring renal replacement therapy, mechanical ventilation, and treatment with vasoactive drugs. Because the bleeding did not respond to fresh-frozen plasma administration, the patient received therapeutic plasma exchange, which was accompanied by a marked improvement of the clinical and biochemical parameters, including a significant decline in serum ferritin levels.

Entities:  

Mesh:

Year:  2019        PMID: 31309922      PMCID: PMC6726932          DOI: 10.4269/ajtmh.19-0219

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  20 in total

1.  Hepatocyte lesions and cellular immune response in yellow fever infection.

Authors:  Juarez A S Quaresma; Vera L R S Barros; Carla Pagliari; Elaine R Fernandes; Heitor F Andrade; Pedro F C Vasconcelos; Maria I S Duarte
Journal:  Trans R Soc Trop Med Hyg       Date:  2006-07-26       Impact factor: 2.184

2.  Advanced yellow fever virus genome detection in point-of-care facilities and reference laboratories.

Authors:  Cristina Domingo; Pranav Patel; Jasmin Yillah; Manfred Weidmann; Jairo A Méndez; Emmanuel Rivalyn Nakouné; Matthias Niedrig
Journal:  J Clin Microbiol       Date:  2012-10-10       Impact factor: 5.948

Review 3.  Current Evidence for Extracorporeal Liver Support Systems in Acute Liver Failure and Acute-on-Chronic Liver Failure.

Authors:  Constantine J Karvellas; Ram M Subramanian
Journal:  Crit Care Clin       Date:  2016-07       Impact factor: 3.598

4.  Revisiting the liver in human yellow fever: virus-induced apoptosis in hepatocytes associated with TGF-beta, TNF-alpha and NK cells activity.

Authors:  Juarez A S Quaresma; Vera L R S Barros; Carla Pagliari; Elaine R Fernandes; Fernanda Guedes; Cleusa F H Takakura; Heitor F Andrade; Pedro F C Vasconcelos; Maria I S Duarte
Journal:  Virology       Date:  2005-11-08       Impact factor: 3.616

5.  Pathophysiologic correlations in a rhesus monkey model of yellow fever with special observations on the acute necrosis of B cell areas of lymphoid tissues.

Authors:  T P Monath; K R Brinker; F W Chandler; G E Kemp; C B Cropp
Journal:  Am J Trop Med Hyg       Date:  1981-03       Impact factor: 2.345

6.  Standardization of immunoglobulin M capture enzyme-linked immunosorbent assays for routine diagnosis of arboviral infections.

Authors:  D A Martin; D A Muth; T Brown; A J Johnson; N Karabatsos; J T Roehrig
Journal:  J Clin Microbiol       Date:  2000-05       Impact factor: 5.948

Review 7.  Molecular pathogenesis of viral hemorrhagic fever.

Authors:  Christopher F Basler
Journal:  Semin Immunopathol       Date:  2017-05-29       Impact factor: 9.623

8.  Epidemiological and laboratory characterization of a yellow fever outbreak in northern Uganda, October 2010-January 2011.

Authors:  Joseph F Wamala; Mugagga Malimbo; Charles L Okot; Ann D Atai-Omoruto; Emmanuel Tenywa; Jeffrey R Miller; Stephen Balinandi; Trevor Shoemaker; Charles Oyoo; Emmanuel O Omony; Atek Kagirita; Monica M Musenero; Issa Makumbi; Miriam Nanyunja; Julius J Lutwama; Robert Downing; Anthony K Mbonye
Journal:  Int J Infect Dis       Date:  2012-05-08       Impact factor: 3.623

Review 9.  What Does the Future Hold for Yellow Fever Virus? (II).

Authors:  Raphaëlle Klitting; Carlo Fischer; Jan F Drexler; Ernest A Gould; David Roiz; Christophe Paupy; Xavier de Lamballerie
Journal:  Genes (Basel)       Date:  2018-08-21       Impact factor: 4.096

10.  Macrophage Activation Marker Soluble CD163 Associated with Fatal and Severe Ebola Virus Disease in Humans1.

Authors:  Anita K McElroy; Punya Shrivastava-Ranjan; Jessica R Harmon; Roosecelis B Martines; Luciana Silva-Flannery; Timothy D Flietstra; Colleen S Kraft; Aneesh K Mehta; G Marshall Lyon; Jay B Varkey; Bruce S Ribner; Stuart T Nichol; Sherif R Zaki; Christina F Spiropoulou
Journal:  Emerg Infect Dis       Date:  2019-02       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.